Hikma Unveils Affordable Victoza® Generic

Hikma Pharmaceuticals PLC, a global leader in pharmaceuticals, has announced the launch of its FDA-approved generic version of Victoza®, Liraglutide Injection, in a 6 mg/mL dosage. This product, a Glucagon-Like Peptide-1 (GLP-1) treatment, is designed to help improve glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, in combination with diet and exercise.

Expanding Access to Diabetes Care

Dr. Bill Larkins, President of Injectables at Hikma, expressed the company’s commitment to addressing diabetes care:
“We are very pleased to launch Liraglutide Injection immediately upon FDA approval, offering an important, affordable generic option for diabetes treatment. This reflects our ongoing efforts to expand our portfolio in therapeutic areas like diabetes while ensuring patients and healthcare providers have access to high-quality, reliable medicines.”

A Growing Need for Affordable Diabetes Treatments

Diabetes remains a significant public health challenge, and the availability of affordable medications like Liraglutide Injection plays a critical role in patient care. According to IQVIA, sales of Liraglutide Injection (6 mg/mL) in the US totaled approximately $1.3 billion in the 12 months leading up to October 2024, underscoring the demand for this essential treatment.

Hikma's Commitment to Quality and Innovation

Hikma is a leading supplier of generic injectable medicines in the US, ranking among the top three by volume. With a portfolio exceeding 170 products, the company continues to expand its offerings in essential medicines and innovative dosage forms to enhance patient care.

This latest launch reinforces Hikma’s mission to provide affordable, high-quality pharmaceuticals while supporting the growing needs of patients and healthcare professionals in critical areas like diabetes management.